Amgen chose a different option for its potential entry into the weight loss drug market with an injectable treatment called MariTide, which has shown potential to help patients who take it keep the weight off even after they stop taking the treatment. Amgen is currently evaluating how MariTide blocks GIP, a second hormone receptor, and is in trials to see if it can be taken monthly or even less frequently and the company is expected to release midstage data on MariTide later this year together with results from a Phase 1 trial for its obesity pill.